Emyria agrees licensing and commercialisation deal for EMD-RX5

Name: Emyria agrees licensing and commercialisation deal for EMD-RX5
Uploaded: 2023-04-04T13:47:00Z
Description: Emyria agrees licensing and commercialisation deal for EMD-RX5

Proactive Published 04/04/2023

Share X in f @

Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has signed a deal with Aspen Pharmacare (JSE:APN) Australia for the licensing and commercialisation of EMD-RX5. The agreement supports the registration and commercialisation of EMD-RX5 as an over-the-counter (OTC) treatment in Australia.